Literature DB >> 16055808

Clinical characteristics of first-admitted patients with ICD-10 schizotypal disorder.

Peter Handest1, Josef Parnas.   

Abstract

BACKGROUND: The clinical picture of schizotypal disorders is rarely comprehensively described. AIMS: To describe psychopathological profiles of patients with ICD-10 schizotypal disorder.
METHOD: A total of 151 first-admitted patients (with affective and somatic disorders excluded) were given a comprehensive psychopathological evaluation, including the Bonn Scale for the Assessment of Basic Symptoms. Patients with schizotypal disorder (n=50) were compared with those with psychosis (n=51) and those outside the schizophrenia spectrum (other diagnoses, n=50) on a number of psychopathological scales.
RESULTS: Patients with schizotypal disorder scored intermediately between patients with psychosis and other diagnoses on scales related to positive and negative symptoms, disorders of emotional contact and formal thought disorder, but had the same scores as patients with schizophrenia for subtle aberrations of subjective experience. Schizotypal criteria were not normally distributed with an excess of patients between 2 and 6 criteria. Family history of schizophrenia was equally elevated among those with schizotypal disorder and those with psychosis.
CONCLUSIONS: ICD-10 schizotypy represents a milder, less psychotic, variant of schizophrenia but there is no clear-cut division between the two disorders.

Entities:  

Mesh:

Year:  2005        PMID: 16055808     DOI: 10.1192/bjp.187.48.s49

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  15 in total

1.  Disturbance of minimal self (ipseity) in schizophrenia: clarification and current status.

Authors:  Barnaby Nelson; Josef Parnas; Louis A Sass
Journal:  Schizophr Bull       Date:  2014-03-11       Impact factor: 9.306

2.  Basic self-disturbance predicts psychosis onset in the ultra high risk for psychosis "prodromal" population.

Authors:  Barnaby Nelson; Andrew Thompson; Alison R Yung
Journal:  Schizophr Bull       Date:  2012-02-20       Impact factor: 9.306

Review 3.  Defining psychosis: the evolution of DSM-5 schizophrenia spectrum disorders.

Authors:  Mahendra T Bhati
Journal:  Curr Psychiatry Rep       Date:  2013-11       Impact factor: 5.285

4.  Self-experience in the early phases of schizophrenia: 5-year follow-up of the Copenhagen Prodromal Study.

Authors:  Josef Parnas; Andrea Raballo; Peter Handest; Lennart Jansson; Anne Vollmer-Larsen; Ditte Saebye
Journal:  World Psychiatry       Date:  2011-10       Impact factor: 49.548

Review 5.  The psychiatric interview: validity, structure, and subjectivity.

Authors:  Julie Nordgaard; Louis A Sass; Josef Parnas
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09-23       Impact factor: 5.270

6.  The silent side of the spectrum: schizotypy and the schizotaxic self.

Authors:  Andrea Raballo; Josef Parnas
Journal:  Schizophr Bull       Date:  2010-02-22       Impact factor: 9.306

Review 7.  Revisiting the Basic Symptom Concept: Toward Translating Risk Symptoms for Psychosis into Neurobiological Targets.

Authors:  Frauke Schultze-Lutter; Martin Debbané; Anastasia Theodoridou; Stephen J Wood; Andrea Raballo; Chantal Michel; Stefanie J Schmidt; Jochen Kindler; Stephan Ruhrmann; Peter J Uhlhaas
Journal:  Front Psychiatry       Date:  2016-01-28       Impact factor: 4.157

8.  Looking at the schizophrenia spectrum through the prism of self-disorders: an empirical study.

Authors:  Andrea Raballo; Ditte Sæbye; Josef Parnas
Journal:  Schizophr Bull       Date:  2009-06-15       Impact factor: 9.306

9.  Self-disorders and the schizophrenia spectrum: a study of 100 first hospital admissions.

Authors:  Julie Nordgaard; Josef Parnas
Journal:  Schizophr Bull       Date:  2014-01-29       Impact factor: 9.306

10.  Identity Disturbance, Feelings of Emptiness, and the Boundaries of the Schizophrenia Spectrum.

Authors:  Maja Zandersen; Josef Parnas
Journal:  Schizophr Bull       Date:  2019-01-01       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.